Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc ("Tissue Regenix" or "the Group")

Interim Results for the 6 months ended 31 July 2011

YORK, 10th October 2011 - Tissue Regenix, the regenerative medical devices company which uses animal or human tissue to replace damaged or worn out parts of the human body, today announces its unaudited interim results for the six months ended 31 July 2011.

Operational Highlights

·; Commercialization and IP agreement entered into with development partners in Brazil. This agreement provides world-wide rights (excluding Brazil) to the clinical data arising from the use of the dCELL® process with human donor heart valves

·; Product patent granted for orthopaedic development programme dCELL® Meniscus

Financial Highlights

·; Increased investment in product programmes designed to expand our product offering resulted in an increased loss after tax of £1,261k (H1 2010: £578k, excluding deemed cost of reverse acquisition of £3,749k)

·; Cash and short term deposits as at 31 July 2011 of £4,848k (H1 2010: £6,702k)

Antony Odell, Tissue Regenix Managing Director, commented:

"Tissue Regenix has continued to build on last year's achievements by further adding to our clinical data in support of the dCELL® Platform as well as concluding a deal with our Brazilian development partners that will enable us to develop our technology faster and more cost effectively. Additionally, through this deal we have opened up new opportunities with the acquisition of the global rights (excluding Brazil) to a pipeline of innovative products, including a number of potential near-term revenue generating opportunities. A registry study is being set up in the UK to provide clinical support for the dCELL® Vascular Patch which was showcased at the European society of Vascular Surgery in Athens in September.

With exciting new products in development and a healthy financial position, we believe we are well positioned for growth within the exciting regenerative medicine space."

Enquiries:

FTI Consulting:

Ben Atwell 020 7831 3113

John Dineen

Tissue Regenix:

Antony Odell 01904 435 176

Ian Jefferson

Peel Hunt LLP:

James Steel 020 7418 8852

Vijay Barathan

Chairman's Statement

Overview

Tissue Regenix was formed in 2006 in order to commercialise new technology developed by Leeds University in the field of regenerative medicine. Using our proprietary platform technology, known as dCELL®, our goal is to build a global leader in this exciting area of healthcare. I believe the progress we have made over the year or so since our admission to AIM has been impressive and whilst there is much to do, as always, I believe we can continue to build on the momentum within the business.

The dCell Process

The dCELL® process, which is protected by a library of patents, is used to create biological scaffolds by decellularising human or animal tissue. When used to replace damaged or diseased body parts in humans these scaffolds have been shown to be capable of regeneration and become integrated into the patient's body. The scaffolds are inert on implantation as a result of the dCELL® process, and the subsequent regeneration is a natural bodily function. This means that our products are classified as medical devices and therefore subject to faster, less costly and less risky regulatory approval procedures than, for example, pharmaceutical products.

Product Development

Cardiac

In April 2011 we entered into a commercialization and IP agreement with our development partners in Brazil. This agreement gave us world-wide rights (excluding Brazil) to the clinical data arising from the use of our process with human donor heart valves. Currently in excess of 140 patients have benefitted from the use of our dCELL® heart valve and the results of up to five years data are most encouraging. We are also continuing to develop a dCELL® version of an existing bovine bioprosthetic valve, which is already in use in over 1200 patients. We are planning a further pilot study of our dCELL® porcine valve prior to a full preclinical study planned for early 2012.

Dermis

Earlier this year we announced that we had initiated a pilot study of the use of human donor decellularised skin in the treatment of chronic wounds with our UK development partner, NHS Blood and Transplant. This trial is currently underway and recruitment is progressing but it remains too early to assess when data will be available. We also intend to examine use of this product in plastic surgery and burns.

Vascular

Our dCELL® Vascular Patch continues to attract interest and we are steadily building the clinical evidence needed to fully commercialise it. The two year follow up data is anticipated to be available in early 2012. We are planning to extend the vascular patch's application to cardiac and dura (neurosurgery) and preclinical work will begin shortly in Brazil. We have applied for approval in the USA via the 510k process and are in dialogue with the FDA regarding additional data requests. Preclinical trial results for our Arterial-Vascular graft, which can be used to replace damaged veins and arteries, have been most encouraging and we plan full clinical trials for 2012.

Orthopaedic

Pilot work on the dCELL® porcine meniscal repair product is complete and we have begun preclinical trials. There is a very large clinical need for this product and as yet there are no real competitive products in the market. As pilot work has been completed on meniscal repair we are now able to turn our attention to our porcine ligament repair product.

Financial Review

Revenue of £108k (H1 2010: £112k) was comprised mainly of grant income. The first half of the year was characterised by increased investment in programmes designed to expand our product offering through product line innovations. To this end, administrative expenses increased to £1,466k (H1 2010: £799k) primarily due to increased development spend on new product trials and additional staff costs incurred as we begin to scale up to develop multiple products concurrently. As a result of these investments, operating loss for the period increased to £1,358k (H1 2010: £687k excluding £3,745k of deemed cost on reverse acquisition). Net cash at the end of the period was £4,848k (H1 2010: £6,702k at the end of the prior period).

The Board

Ian Jefferson commenced his appointment as Chief Financial Officer on 13 June 2011. As previously announced, he replaced Mike Bretherton who remains on the board as a Non-Executive Director.

I am also delighted that the two founders of the company have received external recognition. Eileen Ingham received the top award for Innovation and Entrepreneurship in Academia and Research at the UK Research Council's Women of Outstanding Achievement Awards and John Fisher was awarded a CBE in recognition of his services to biomedical engineering.

Outlook

During the period we have seen a continuation of our strategy of working with partners to develop a strong product pipeline at low cost and minimum risk and the commercialization and IP agreement signed with our Brazilian partners has expanded our pipeline of innovative products which address the needs of very large global markets.

The investments we are undertaking to develop new product innovations has ideally positioned Tissue Regenix to capitalise on major global needs and become a leader in regenerative medicine. Our focus therefore is to continue to develop our pipeline of products and seek commercialization for them as soon as we are able. I believe we are making good progress in our endeavours.

John Samuel

Executive Chairman

10 October 2011

The loss for the period arises from the Group's continuing operations.

Approved by the Board and authorised for issue on 10 October 2011

John Samuel (Executive Chairman) Ian Jefferson (Chief Financial Officer)

1. Basis of preparation

The interim financial statements of Tissue Regenix Group Plc are unaudited condensed consolidated financial statements for the six months to 31 July 2011. These include unaudited comparatives for the six months to 31 July 2010 together with the audited accounts for the year to 31 January 2010.

These condensed consolidated financial statements do not constitute statutory accounts. The statutory accounts for the year to 31 January 2011 have been reported on by the auditors to Tissue Regenix Group Plc and have been filed with the Registrar of Companies. The report of the auditors was unqualified and did not contain a statement under section 498 of the Companies Act 2006.

2. Significant accounting policies

The condensed consolidated financial statements have been prepared under the historical cost convention in accordance with International Financial Reporting Standards as adopted by the European Union.

The accounting policies adopted are consistent with those followed in the preparation of the audited financial statements of Tissue Regenix Group Plc for the year ended 31 January 2011 and are disclosed in those statements.

3. Segmental Reporting

At 31 July 2011, the Group operated in one business segment, that of the development and commercialisation of innovative platform technologies in the field of tissue engineering and regenerative medicine.

To date all the revenues comprise grant income earned in the UK. All of the Group's assets are held in the UK and all of its capital expenditure arises in the UK.

4. Taxation

The Group has accumulated losses available to carry forward against future trading profits. No deferred tax asset has been recognised in respect of tax losses as their recoverability is uncertain.

5. Loss per share (basic and diluted)

Basic loss per share is calculated by dividing the loss attributable to equity holders of the parent by the weighted average number of ordinary shares in issue during the period excluding own shares held jointly by the Tissue Regenix Employee Share Trust and certain employees. Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue during the period to assume conversion of all dilutive potential ordinary shares.

The Company has issued employees options over 14,629,309 ordinary shares which are potentially dilutive. There is, however, no dilutive effect of these issued options as there is a loss for each of the periods concerned.

6. Share capital

As permitted by the provisions of the Companies Act 2006, the Company does not have an upper limit to its authorised share capital.

7. Movement in revenue reserve and own shares

8. Interim financial report

A copy of this interim report will be distributed to shareholders and is also available on the Company's website at www.tissueregenix.com